PARG and colorectal carcinoma: Our findings demonstrate for the first time, that inhibiting PARG, either genetically or pharmacologically, enhances sensitivity to chemotherapy, particularly to 5FU and the FUIRI combination and suggest that PARG inhibition could be a promising strategy to improve treatment efficacy in CRC patients.